Obstetrics and Gynaecology, The University of Melbourne Faculty of Medicine Dentistry and Health Sciences, Melbourne, Victoria, Australia
Newborn Research Centre, The Royal Women's Hospital, Parkville, Victoria, Australia.
BMJ Open. 2021 Jun 23;11(6):e045897. doi: 10.1136/bmjopen-2020-045897.
Respiratory distress syndrome is a complication of prematurity and extremely preterm infants born before 28 weeks' gestation often require endotracheal intubation and mechanical ventilation. In this high-risk population, mechanical ventilation is associated with lung injury and contributes to bronchopulmonary dysplasia. Therefore, clinicians attempt to extubate infants as quickly and use non-invasive respiratory support such as nasal continuous positive airway pressure (CPAP) to facilitate the transition. However, approximately 60% of extremely preterm infants experience 'extubation failure' and require reintubation. While CPAP pressures of 5-8 cm H2O are commonly used, the optimal CPAP pressure is unknown, and higher pressures may be beneficial in avoiding extubation failure. Our trial is the Extubation CPAP Level Assessment Trial (ÉCLAT). The aim of this trial is to compare higher CPAP pressures 9-11 cm H2O with a current standard pressures of 6-8 cmH2O on extubation failure in extremely preterm infants.
200 extremely preterm infants will be recruited prior to their first extubation from mechanical ventilation to CPAP. This is a parallel group randomised controlled trial. Infants will be randomised to one of two set CPAP pressures: CPAP 10 cmH2O (intervention) or CPAP 7 cmH2O (control). The primary outcome will be extubation failure (reintubation) within 7 days. Statistical analysis will follow standard methods for randomised trials on an intention to treat basis. For the primary outcome, this will be by intention to treat, adjusted for the prerandomisation strata (GA and centre). We will use the appropriate parametric and non-parametric statistical tests.
Ethics approval has been granted by the Monash Health Human Research Ethics Committees. Amendments to the trial protocol will be submitted for approval. The findings of this study will be written into a clinical trial report manuscript and disseminated via peer-reviewed journals (on-line or in press) and presented at national and international conferences.ACTRN12618001638224; pre-results.
呼吸窘迫综合征是早产儿的并发症,极早产儿(胎龄 28 周前出生)通常需要气管内插管和机械通气。在这个高危人群中,机械通气与肺损伤有关,并导致支气管肺发育不良。因此,临床医生试图尽快为婴儿拔管,并使用鼻持续气道正压通气(CPAP)等非侵入性呼吸支持来促进过渡。然而,大约 60%的极早产儿会出现“拔管失败”,需要重新插管。虽然通常使用 5-8cmH2O 的 CPAP 压力,但最佳 CPAP 压力尚不清楚,较高的压力可能有助于避免拔管失败。我们的试验是拔管 CPAP 压力评估试验(ÉCLAT)。该试验的目的是比较极早产儿首次从机械通气转为 CPAP 时,9-11cmH2O 的较高 CPAP 压力与目前 6-8cmH2O 的标准压力对拔管失败的影响。
将在机械通气转为 CPAP 前,从 200 例极早产儿中招募,进行平行组随机对照试验。婴儿将被随机分配到两组 CPAP 压力之一:CPAP 10cmH2O(干预组)或 CPAP 7cmH2O(对照组)。主要结局是 7 天内拔管失败(再插管)。统计分析将遵循随机试验的标准方法,基于意向治疗进行。对于主要结局,这将是基于意向治疗,调整为预随机化分层(GA 和中心)。我们将使用适当的参数和非参数统计检验。
莫纳什健康人体研究伦理委员会已批准该试验。将提交试验方案修正案供批准。这项研究的结果将写入临床试验报告手稿,并通过同行评议期刊(在线或即将出版)传播,并在国家和国际会议上报告。ACTRN12618001638224;预结果。